JP2018531625A - 脳への向上した薬物送達の方法 - Google Patents

脳への向上した薬物送達の方法 Download PDF

Info

Publication number
JP2018531625A
JP2018531625A JP2018532523A JP2018532523A JP2018531625A JP 2018531625 A JP2018531625 A JP 2018531625A JP 2018532523 A JP2018532523 A JP 2018532523A JP 2018532523 A JP2018532523 A JP 2018532523A JP 2018531625 A JP2018531625 A JP 2018531625A
Authority
JP
Japan
Prior art keywords
antibody
binding protein
antigen binding
seq
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531625A5 (enExample
Inventor
マーク シー． グラッシー
マーク シー． グラッシー
リシャブ ケイ． グプタ
リシャブ ケイ． グプタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018531625A publication Critical patent/JP2018531625A/ja
Publication of JP2018531625A5 publication Critical patent/JP2018531625A5/ja
Priority to JP2021127980A priority Critical patent/JP2021191269A/ja
Priority to JP2023104613A priority patent/JP7361980B2/ja
Priority to JP2023172056A priority patent/JP2024001124A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018532523A 2015-09-11 2016-09-09 脳への向上した薬物送達の方法 Pending JP2018531625A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021127980A JP2021191269A (ja) 2015-09-11 2021-08-04 脳への向上した薬物送達の方法
JP2023104613A JP7361980B2 (ja) 2015-09-11 2023-06-27 脳への向上した薬物送達の方法
JP2023172056A JP2024001124A (ja) 2015-09-11 2023-10-03 脳への向上した薬物送達の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217608P 2015-09-11 2015-09-11
US62/217,608 2015-09-11
US201562247490P 2015-10-28 2015-10-28
US62/247,490 2015-10-28
PCT/US2016/051128 WO2017044866A2 (en) 2015-09-11 2016-09-09 Enhanced delivery of drugs to the brain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021127980A Division JP2021191269A (ja) 2015-09-11 2021-08-04 脳への向上した薬物送達の方法

Publications (2)

Publication Number Publication Date
JP2018531625A true JP2018531625A (ja) 2018-11-01
JP2018531625A5 JP2018531625A5 (enExample) 2019-10-17

Family

ID=58236547

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018532523A Pending JP2018531625A (ja) 2015-09-11 2016-09-09 脳への向上した薬物送達の方法
JP2021127980A Pending JP2021191269A (ja) 2015-09-11 2021-08-04 脳への向上した薬物送達の方法
JP2023104613A Active JP7361980B2 (ja) 2015-09-11 2023-06-27 脳への向上した薬物送達の方法
JP2023172056A Pending JP2024001124A (ja) 2015-09-11 2023-10-03 脳への向上した薬物送達の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021127980A Pending JP2021191269A (ja) 2015-09-11 2021-08-04 脳への向上した薬物送達の方法
JP2023104613A Active JP7361980B2 (ja) 2015-09-11 2023-06-27 脳への向上した薬物送達の方法
JP2023172056A Pending JP2024001124A (ja) 2015-09-11 2023-10-03 脳への向上した薬物送達の方法

Country Status (7)

Country Link
US (2) US11028155B2 (enExample)
EP (2) EP4548979A3 (enExample)
JP (4) JP2018531625A (enExample)
AU (2) AU2016319133B2 (enExample)
CA (1) CA2998132A1 (enExample)
IL (1) IL257983A (enExample)
WO (1) WO2017044866A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544358A (ja) * 2021-10-29 2024-11-29 ナセント バイオテック インコーポレイテッド ビメンチンを発現する腫瘍を治療するためのキットおよび容器

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998132A1 (en) 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
US11492394B1 (en) 2021-10-29 2022-11-08 Nascent Biotech, Inc. Kits and containers for treating vimentin expressing tumors
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
ES2149867T3 (es) 1993-02-26 2000-11-16 Drug Delivery System Inst Ltd Derivados de polisacaridos y soportes para farmacos.
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
IL112920A (en) 1994-03-07 2003-04-10 Dow Chemical Co Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
US5786387A (en) 1994-03-23 1998-07-28 Meiji Seika Kabushiki Kaisha Lipid double-chain derivative containing polyoxyethylene
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
EP2221315A1 (en) * 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006101692A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
PT2073842E (pt) * 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
CN114634572A (zh) 2011-10-10 2022-06-17 希望之城公司 中间位和中间位结合抗体及其用途
ES2938182T3 (es) * 2012-04-30 2023-04-05 Biocon Ltd Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas
US20150218280A1 (en) * 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
CA2998132A1 (en) 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 746, JPN6021011471, 2012, pages 121 - 141, ISSN: 0004479020 *
BIOTECHNOLOGY AND BIOENGINEERING, 2007, VOL. 96, NO. 2, P.381-391, JPN6020035691, ISSN: 0004349305 *
HUMANISING ANTIBODIES BY CDR GRAFTING, ANTIBODY ENGINEERING VOL. 1, 2010, P.319-339, JPN6020035689, ISSN: 0004349304 *
MONOCLONAL ANTIBODY THERAPY FOR MALIGNANT GLIOMA, ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (20, JPN6020035694, ISSN: 0004349307 *
NIPPON RINSHO、2002、60巻3号、P.497-503, JPN6020035696, ISSN: 0004349303 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, VOL. 284, NO. 5, PP. 3273-3284, JPN6020035692, ISSN: 0004349306 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544358A (ja) * 2021-10-29 2024-11-29 ナセント バイオテック インコーポレイテッド ビメンチンを発現する腫瘍を治療するためのキットおよび容器

Also Published As

Publication number Publication date
JP2023126840A (ja) 2023-09-12
AU2016319133A1 (en) 2018-04-05
AU2016319133B2 (en) 2023-06-08
CA2998132A1 (en) 2017-03-16
EP3347380B1 (en) 2024-09-25
HK1256875A1 (en) 2019-10-04
JP2024001124A (ja) 2024-01-09
JP7361980B2 (ja) 2023-10-16
WO2017044866A3 (en) 2017-06-08
US11028155B2 (en) 2021-06-08
EP3347380A4 (en) 2019-05-08
US20170073400A1 (en) 2017-03-16
US20210269513A1 (en) 2021-09-02
AU2023226718A1 (en) 2023-09-28
EP3347380A2 (en) 2018-07-18
EP4548979A2 (en) 2025-05-07
WO2017044866A2 (en) 2017-03-16
JP2021191269A (ja) 2021-12-16
IL257983A (en) 2018-05-31
EP4548979A3 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
JP7412521B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
JP7361980B2 (ja) 脳への向上した薬物送達の方法
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP6862435B2 (ja) 抗ｗｔ１／ｈｌａ特異的抗体
JP7663883B2 (ja) Ｃｌｄｎ１８．２抗体及びその使用
US12479922B2 (en) Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity
CN113454112A (zh) 识别tau的抗体
AU2021218927B2 (en) Claudin 18.2 antibody and use thereof
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
CN118388652A (zh) 抗成纤维细胞活化蛋白的单克隆抗体及其应用
CN113248611A (zh) 抗bcma抗体、其药物组合物及应用
HK1256875B (en) Enhanced delivery of drugs to the brain
TW202544048A (zh) 新穎預靶向抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210405